Showing results (161-170 of 618) with videos related to

Sort By:
Pageof 62
Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERTManmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, et al.
Annual Review of Cancer Biology|February 7, 2024
The Blood-Brain Barrier: Implications for Experimental Cancer TherapeuticsJoelle P Straehla, David A Reardon, Patrick Y Wen, et al.
Neuro-Oncology|January 9, 2015
Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trialsLorenzo Trippa, Patrick Y Wen, Giovanni Parmigiani, et al.
Current Opinion in Oncology|July 16, 2024
RANO 2.0 criteria: concepts applicable to the neuroradiologist's clinical practiceFrancesco Sanvito, Antonella Castellano, Timothy F Cloughesy, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 16, 2021
The effects of SmartCare© on neuro-oncology family caregivers' distress: a randomized controlled trialFlorien W Boele, Jason M Weimer, Anna L Marsland, et al.
Neuro-Oncology|February 24, 2016
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapyEudocia Q Lee, Alona Muzikansky, Jan Drappatz, et al.
Neuro-Oncology|April 5, 2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastomaAndrew D Norden, Glenn J Lesser, Jan Drappatz, et al.
Neurosurgery|October 2, 2025
Corticosteroid Use Before Stereotactic Brain Biopsy for Suspected LymphomaMaged T Ghoche, Kenji Miki, Skyler Oken, et al.
Neuro-Oncology|April 17, 2018
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastomaBenjamin M Ellingson, Dana T Aftab, Gisela M Schwab, et al.
Pageof 62